IRIX - イリデックス （IRIDEX Corporation） イリデックスIRIXのチャート
IRIXの企業情報
| symbol | IRIx |
|---|---|
| 会社名 | IRIDEX Corp. （イリデックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Electromedical_Electrotherapeutic Apparatus |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 イリデックス（IRIDEX Corporation）は眼科学における目の疾患の治療用の治療ベースのレーザーシステム、送達デバイス及び消耗器具のグローバルなプロバイダー。同社は主に眼科に集中する。同社の眼科治療商品は主に直販の方式で米国内に販売されて、100カ国以上における約70の独立系代理販売業者を介して国際的に販売される。同社の眼科治療商品は「IQ」と「OcuLight」レーザーシステム、消耗品、及びサービスと支援業務を含む。同社の「IQ」製品群は「IQ 532」、「IQ 577」と「IQ 810」のレーザー光凝固システムを含み、「OcuLight」商品は「OcuLight TX」、「OcuLight Symphony」（レーザー・デリバリー・システム）、「OcuLight SL」、「OcuLight SLx」、「OcuLight GL」及び「OcuLight GLx」のレーザー光凝固システムを含む。平成24年2月、同社はCutera Inc.に美容事業を譲渡した。 イリデックスは医療用レ―ザ―システムを提供する米国企業。眼疾患治療に使用されるレ―ザ―システム、送達デバイス及び消耗器具類などを開発、製造。糖尿病性網膜症、緑内障、加齢性黄斑変性症などの視力を脅かす眼の疾患を対象とする。販売代理店を通じて、世界的に製品を販売。本社はカリフォルニア州。 Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company's proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex's current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. |
| 本社所在地 | 1212 Terra Bella Avenue Mountain View CA 94043-1824 USA |
| 代表者氏名 | William M. Moore ウィリアム・M・ムーア |
| 代表者役職名 | Chairman of the Board Interim President and Chief Executive Officer |
| 電話番号 | +1 650-940-4700 |
| 設立年月日 | 32540 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1996年 |
| 従業員数 | 154人 |
| url | www.iridex.com |
| nasdaq_url | https://www.nasdaq.com/symbol/irix |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -14.49200 |
| 終値（lastsale） | 5.925 |
| 時価総額（marketcap） | 69110260.575 |
| 時価総額 | 時価総額（百万ドル） 69.31863 |
| 売上高 | 売上高（百万ドル） 40.92100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 53.27363 |
| 当期純利益 | 当期純利益（百万ドル） -15.13400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 IRIDEX Corporation revenues decreased 3% to $19.8M. Net loss increased 49% to $6.9M. Revenues reflect United States segment decrease of 14% to $10M Asia/Pacific Rim segment decrease of 2% to $3.9M. Higher net loss reflects Selling/General/Admin. Expense increase of 26% to $8M (expense) Selling expenses increase of 25% to $4.4M (expense). |
IRIXのテクニカル分析
IRIXのニュース
IRIDEX (IRIX) Investor Presentation - Slideshow 2023/03/29 12:32:58 Seeking Alpha
The following slide deck was published by IRIDEX Corporation in conjunction with this event.
Iridex''s Return On Capital Employed Insights 2023/03/14 14:48:36 Benzinga
According to Benzinga Pro data, during Q4, Iridex (NASDAQ: IRIX ) posted sales of $15.20 million. Earnings were up 35.03%, but Iridex still reported an overall loss of $1.15 million. Iridex collected $14.63 million in revenue during Q3, but reported earnings showed a $1.77 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com
IRIDEX Corp PT Lowered to $6.25 at Roth/MKM 2023/03/10 11:36:02 Investing.com
https://www.investing.com/news/pro/iridex-corp-pt-lowered-to-625-at-rothmkm-432SI-3027418
IRIDEX Corporation (IRIX) Q4 2022 Earnings Call Transcript 2023/03/10 03:12:04 Seeking Alpha
IRIDEX Corporation (NASDAQ:NASDAQ:IRIX) Q4 2022 Earnings Conference Call March 9, 2023 5:00 PM ETCompany ParticipantsPhilip Taylor - Investor Relations, Gilmartin GroupDavid Bruce -…
Iridex: Q4 Earnings Snapshot 2023/03/09 21:55:24 WTOP
MOUNTAIN VIEW, Calif. (AP) — MOUNTAIN VIEW, Calif. (AP) — Iridex Corp. (IRIX) on Thursday reported a loss of $1.1…
IRIDEX Corp PT Lowered to $8.25 at Roth Capital 2022/11/15 08:32:06 Investing.com
https://www.investing.com/news/pro/iridex-corp-pt-lowered-to-825-at-roth-capital-432SI-2944238
Iridex stock rises after reporting Q3 results beat, reaffirming FY 2022 guidance 2022/11/11 19:01:44 Seeking Alpha
Shares of micro-cap eye-lasers procedure company Iridex (IRIX) rose as much as 11.4% to $2.25 in Friday afternoon trading, after it reported a Q3 results beat and reaffirmed its FY…
IRIDEX Corporation (IRIX) Q3 2022 Earnings Call Transcript 2022/11/11 03:11:03 Seeking Alpha
IRIDEX Corporation (NASDAQ:NASDAQ:IRIX) Q3 2022 Results Conference Call November 10, 2022 05:00 PM ET Company Participants David Bruce - Chief Executive Officer Fuad Ahmad - Interim Chief…
UBX, ACDC and EXFY are among after hour movers 2022/11/10 23:03:30 Seeking Alpha
Gainers: IRIDEX (IRIX) +14%. Matterport (MTTR) +12%
IRIDEX Earnings, Revenue Beat in Q3 By Investing.com 2022/11/10 22:36:00 Investing.com
IRIDEX Earnings, Revenue Beat in Q3
Iridex''s Cyclo G6 platform for treating glaucoma gets regulatory clearance in China 2022/06/14 14:02:34 Seeking Alpha
Iridex (IRIX) on Tuesday said it had got Chinese regulatory clearance to market and sell its Cyclo G6 platform for the treatment of glaucoma diseases.IRIX and its distribution…
Iridex Obtains Regulatory Clearance for Cyclo G6® Glaucoma Platform in China 2022/06/14 13:21:00 GlobeNewswire
MOUNTAIN VIEW, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced that it has received regulatory clearance to market and sell its Cyclo G6 ® platform for the treatment of glaucoma diseases in China by its National Medical Products Administration (NMPA). In accordance with the clearance, Iridex and distribution partners Topcon and Clinico will launch the Cyclo G6 system and related probes in China beginning in the third quarter of 2022.
Iridex Obtains Regulatory Clearance for Cyclo G6 Glaucoma Platform in China 2022/06/14 13:21:00 Wallstreet:Online
MOUNTAIN VIEW, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, today announced that it has received regulatory clearance to market and sell its Cyclo G6 platform for the treatment of glaucoma diseases in China by its National Medical Products Administration
Rate - IRIDEX Stock Rating Upgraded by Zacks Investment Research 2022/06/02 06:09:08 Business Mag
IRIDEX was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Thursday, Zacks.com reports. According to Zacks…
IRIDEX Corporation''s (IRIX) CEO David Bruce on Q1 2022 Results - Earnings Call Transcript 2022/05/13 02:06:05 Seeking Alpha
IRIDEX Corporation (NASDAQ:NASDAQ:IRIX) Q1 2022 Earnings Conference Call May 12, 2022 5:00 PM ET Company Participants David Bruce – Chief Executive Officer Hunter Cabi – Investor Relations…